Gilead Sciences Inc on Wednesday took the unusual step of asking the U.S. Food a...
- Gilead Sciences Inc on Wednesday took the unusual step of asking the U.S. Food and Drug Administration to rescind a controversial orphan drug designation the agency had granted for the biotech company’s potential coronavirus treatment remdesivir just 48 hours earlier.
The drug, which previously failed as an Ebola treatment, is being tried on COVID-19 patients. It has been described by U.S. President Donald Trump and health officials as one of the more promising candidates to fight the virus. The FDA said there have previously been four approved orphan drugs that had the designation withdrawn by their sponsor.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA Approves More ‘Rapid’ COVID-19 Coronavirus Tests For Use On FrontlinesThe U. S. Food and Drug Administration is approving more rapid molecular diagnostic tests that can be used in temporary screening locations, doctor’s office labs and nursing homes to detect the Coronavirus strain COVID-19 in less than a half hour.
Leer más »
FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease TreatmentsThe FDA has given remdesivir, an experimental drug for COVID-19, 'orphan drug status.' The decision comes with lucrative incentives to drugmaker Gilead Sciences — including tax breaks and a 7-year monopoly on the drug if it's approved.
Leer más »
FDA Approved Drugs Show Promise Against COVID-19Two promising new studies suggest that dozens of drugs already approved for use in the United States may prove effective against the new coronavirus.
Leer más »
FDA will allow doctors to treat critically ill coronavirus patients with blood from survivorsUnder new emergency protocols approved Tuesday, FDA will allow doctors across the US to begin using plasma donated by coronavirus survivors to treat patients who are critically ill with the virus.
Leer más »